Additionally, the 36-month beta value for TNXP is 1.65. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of TNXP on April 24, 2025 was 1.67M shares.
TNXP) stock’s latest price update
The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has jumped by 13.77 compared to previous close of 14.96. Despite this, the company has seen a gain of 0.12% in its stock price over the last five trading days. globenewswire.com reported 2025-04-16 that CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C.
TNXP’s Market Performance
TNXP’s stock has risen by 0.12% in the past week, with a monthly drop of -44.22% and a quarterly drop of -46.65%. The volatility ratio for the week is 8.66% while the volatility levels for the last 30 days are 14.98% for Tonix Pharmaceuticals Holding Corp The simple moving average for the past 20 days is -6.18% for TNXP’s stock, with a -32.93% simple moving average for the past 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at 10.74% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.47% of loss for the given period.
Volatility was left at 14.98%, however, over the last 30 days, the volatility rate increased by 8.66%, as shares sank -42.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.55% upper at present.
During the last 5 trading sessions, TNXP rose by +0.12%, which changed the moving average for the period of 200-days by -78.73% in comparison to the 20-day moving average, which settled at $18.14. In addition, Tonix Pharmaceuticals Holding Corp saw -48.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.7 for the present operating margin
- 0.23 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -12.88. The total capital return value is set at -0.54. Equity return is now at value -106.12, with -81.95 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -11.41.
Currently, EBITDA for the company is -71.73 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 0.17. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.50.
Conclusion
In conclusion, Tonix Pharmaceuticals Holding Corp (TNXP) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
